Korean Post-marketing Surveillance for Somavert
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Adverse reactions
- Sponsors Pfizer
- 18 Sep 2023 Planned primary completion date changed from 2 Aug 2026 to 15 Sep 2026.
- 31 Aug 2022 Status changed from not yet recruiting to recruiting.
- 18 Jul 2022 Planned initiation date changed from 30 May 2022 to 15 Aug 2022.